Search Results for: "Clinic Roundup"
-
Pharma: Clinic Roundup
All doses showed statistically significant separation from placebo starting at week two and at each subsequent time point, with the highest dose showing separation as early as week one of treatmentBioWorld Today | Wednesday, February 29, 2012 -
Clinic Roundup
In the highest dose group, that increase continued throughout the three-month follow-up period, and no ITP rescue treatment was necessary in those patientsBioWorld Today | Wednesday, February 15, 2012 -
Clinic Roundup
PG-free Melphalan, administered as half of a high-dose conditioning regimen, resulted in successful myeloablation (100 percent of patients) and subsequent engraftment (100 percent of patients) with no additional toxicityBioWorld Today | Friday, February 3, 2012 -
Clinic Roundup
Spectrum Pharmaceuticals Inc., of Henderson, Nev., said a randomized study, published online in Cancer, concluded that standard-dose Zevalin (ibritumomab tiuxetan) injection combined with beam high-dose chemotherapy is safe and possibly more effective than beam alone as a conditioning regimen for autologous stem-cell transplantation (ASCTBioWorld Today | Tuesday, January 24, 2012 -
Clinic Roundup
Thallion Pharmaceuticals Inc., of Montreal, and LFB Biotechnologies, of Les Ulis, France, have completed patient enrollment for the high-dose cohort (3 mg/kg) of a Phase II SHIGATEC trial, evaluating Shigamabs to treat Shiga toxin-producing EBioWorld Today | Tuesday, January 10, 2012 -
Clinic Roundup
AVI BioPharma Inc., of Bothell, Wash., said an independent data safety monitoring board determined that the Phase IIb study of eteplirsen in Duchenne's muscular dystrophy (DMD) was safe to proceed as planned following a review of the 12-week biopsy data from the highest dose cohort (50 mg/kg...The drug showed no dose-limiting toxicities up to and including the highest dose of 6 mg and, after three months of follow-up, patients treated by a single dose of QPI-1007 exhibited no further loss of visualBioWorld Today | Thursday, January 5, 2012 -
Clinic Roundup
Chelsea Therapeutics International Ltd., of Charlotte, N.C., said a Phase II trial showed the highest dose tested of droxidopa, 600 mg TID, resulted in a 6.2-point improvement from a baseline and a 3.2-point pain improvement over placebo in a questionnaire for fibromyaligiaBioWorld Today | Tuesday, December 27, 2011 -
Clinic Roundup
Repros Therapeutics Inc., of The Woodlands, Texas, reported top-line Phase II data showing Androxal significantly increased testosterone levels at both the low and high doses vs...There was a trend toward improved glycemic control in the men on the higher doseBioWorld Today | Wednesday, December 14, 2011 -
Clinic Roundup
Metabolex Inc., of Hayward, Calif., said an open-label clinical pharmacology study showed that the higher dose of arhalofenate plus Osaka, Japan-based Takeda Pharmaceutical CoBioWorld Today | Friday, December 9, 2011 -
Clinic Roundup
The highest dose of the drug reduced mortality by 68 percent in the second stage of the trial (p = 0.07BioWorld Today | Tuesday, November 22, 2011 -
Clinic Roundup
the high dose of atorvastatin alone in patients with primary hypercholesterolemia with elevated cholesterol who were on a stable low dose (10 mg) of atorvastatinBioWorld Today | Friday, November 11, 2011 -
Clinic Roundup
Inc., of Whitehouse Station, N.J., recently completed an additional multiple rising-dose Phase I study to explore higher doses of oral vernakalant, and data showed the drug was well toleratedBioWorld Today | Monday, November 7, 2011 -
Clinic Roundup
The Captisol-enabled product is designed to allow for longer administration and slower infusion rates, potentially allowing clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapyBioWorld Today | Thursday, November 3, 2011 -
Clinic Roundup
The double-blind trial will enroll 160 subjects with incomplete responses to a VEGF inhibitor to receive a VEGF inhibitor alone, VEGF inhibitor plus low-dose iSONEP, VEGF inhibitor plus high-dose iSONEP, and iSONEP aloneBioWorld Today | Tuesday, October 18, 2011 -
Clinic Roundup
standard of care in the first cohort, while the second cohort will compare standard of care combined with high dose of Shigamabs vsBioWorld Today | Thursday, October 13, 2011 -
Clinic Roundup
Pevion Biotech AG, of Bern, Switzerland, reported the latest results from its ongoing clinical study of volunteers vaccinated with the intramuscular high dose of Candida vaccine PEV7, showing high levels of specific antibodies and a 100 percent mucosal immune response rateBioWorld Today | Wednesday, October 12, 2011 -
Clinic Roundup
The 250-mg, twice-daily dose was found to be acceptable, while the two highest doses were terminated due to infections and deathsBioWorld Today | Wednesday, September 28, 2011 -
Clinic Roundup
Bionomics Ltd., of Adelaide, Australia, said the higher dose level of 16 mg/m2 was cleared for BNC105, a vascular-disrupting agent that is being tested in a clinical trial in combination with mTOR inhibitor Afinitor (everolimus, Novartis AG) in patients with metastatic renal cell cancerBioWorld Today | Wednesday, September 21, 2011 -
Clinic Roundup
The company also initiated an additional Phase Ib trial of INX-189 designed to evaluate higher doses of the drug as a monotherapy or in combination with ribavirin for seven daysBioWorld Today | Tuesday, September 20, 2011 -
Clinic Roundup
ReNeuron Ltd., of Guildford, UK, received clearance from an independent data safety monitoring board to advance to a higher dose of stem cell treatment ReN001 in its Phase I trial for strokeBioWorld Today | Friday, September 2, 2011
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.